Compound 12g(Shenyang Pharmaceutical University)

The P2Y₁ receptor is a promising target for treating an ischemic stroke. Herein, a conformational restriction strategy was applied to improve the brain exposure of our previously reported P2Y₁ antagonist HNW001. Compound 12g, containing an imidazo[1,5-a]pyrazine scaffold, turned out to be a remarkable P2Y₁ antagonist (IC₅₀ = 1.95 μM) with improved brain drug exposure (AUC_{(compound 12g)} = 37.57 μg/g·h vs AUC_(HNW001) = 6.65 μg/g·h) and less bleeding risk, and it also displayed great potential for neuroprotection. Subsequently, the anti-ischemic stroke efficacy of compound 12g was validated using a rat MCAO model (ED₅₀ = 4.49 mg/kg), outperforming HNW001, BPTU, and edaravone. Additionally, compound 12g dose-dependently inhibited infarct sizes in a mouse myocardial infarction model. Collectively, these findings suggested that the imidazo[1,5-a]pyrazine scaffold has potential for developing effective P2Y₁ antagonists, and compound 12g could be a promising anti-ischemic agent for treating ischemic stroke and myocardial infarction.